ZA202102816B - High concentration protein formulation - Google Patents

High concentration protein formulation

Info

Publication number
ZA202102816B
ZA202102816B ZA2021/02816A ZA202102816A ZA202102816B ZA 202102816 B ZA202102816 B ZA 202102816B ZA 2021/02816 A ZA2021/02816 A ZA 2021/02816A ZA 202102816 A ZA202102816 A ZA 202102816A ZA 202102816 B ZA202102816 B ZA 202102816B
Authority
ZA
South Africa
Prior art keywords
high concentration
protein formulation
concentration protein
formulation
compositions
Prior art date
Application number
ZA2021/02816A
Other languages
English (en)
Inventor
Hunter Chen
Erica Schlesinger
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of ZA202102816B publication Critical patent/ZA202102816B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Dispersion Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ZA2021/02816A 2018-11-21 2021-04-28 High concentration protein formulation ZA202102816B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862770337P 2018-11-21 2018-11-21
PCT/US2019/062596 WO2020106948A1 (en) 2018-11-21 2019-11-21 High concentration protein formulation

Publications (1)

Publication Number Publication Date
ZA202102816B true ZA202102816B (en) 2024-08-28

Family

ID=68916589

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2021/02816A ZA202102816B (en) 2018-11-21 2021-04-28 High concentration protein formulation

Country Status (14)

Country Link
US (2) US12036280B2 (cg-RX-API-DMAC7.html)
EP (1) EP3883542A1 (cg-RX-API-DMAC7.html)
JP (1) JP7637618B2 (cg-RX-API-DMAC7.html)
KR (1) KR102944691B1 (cg-RX-API-DMAC7.html)
CN (1) CN113164378A (cg-RX-API-DMAC7.html)
AU (1) AU2019384160B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021009463A2 (cg-RX-API-DMAC7.html)
CA (1) CA3118306A1 (cg-RX-API-DMAC7.html)
EA (1) EA202191403A1 (cg-RX-API-DMAC7.html)
IL (1) IL283229B2 (cg-RX-API-DMAC7.html)
MX (1) MX2021005910A (cg-RX-API-DMAC7.html)
SG (1) SG11202104166QA (cg-RX-API-DMAC7.html)
WO (1) WO2020106948A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202102816B (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS67656B1 (sr) 2018-05-10 2026-02-27 Regeneron Pharma Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
EP4398874A1 (en) * 2021-09-09 2024-07-17 Xeris Pharmaceuticals, Inc. Injectable high concentration pharmaceutical formulations and methods of manufacturing and use thereof
CN122070304A (zh) * 2023-08-24 2026-05-19 瑞泽乐特公司 用于抗胰岛素受体抗体的高浓度调配物和其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1142172B (it) * 1978-10-19 1986-10-08 Sandoz Ag Nuovo impiego in terapeutica della ciclosporina-a e della diidrociclosporina-c
US6659982B2 (en) 2000-05-08 2003-12-09 Sterling Medivations, Inc. Micro infusion drug delivery device
US6629949B1 (en) 2000-05-08 2003-10-07 Sterling Medivations, Inc. Micro infusion drug delivery device
MXPA03001092A (es) * 2000-08-07 2003-09-25 Nektar Therapeutics Al Corp Polvos de proteina de haz de 4 helices secados por rocio, inhalables, que tienen agregacion minimizada.
US20090208492A1 (en) 2007-06-14 2009-08-20 Elan Pharmaceuticals, Inc. Lyophilized Immunoglobulin Formulations and Methods of Preparation
US20110223208A1 (en) 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US9072668B2 (en) * 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
CA2829629A1 (en) * 2011-03-10 2012-09-13 Board Of Regents, The University Of Texas System Protein nanoparticle dispersions
CN103356490A (zh) * 2012-03-29 2013-10-23 复旦大学 可直接固体化的交联食物蛋白稳定化纳米给药系统
SI2849723T1 (sl) * 2012-05-18 2018-09-28 Genentech, Inc. Formulacije z visoko koncentracijo monoklonskih protiteles
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
SMT202200464T1 (it) * 2014-05-06 2023-01-13 S I I T S R L Servizio Int Imballaggi Termosaldanti Formulazione oleosa erogabile tramite spray a base di vitamine liposolubili del gruppo d e relativo uso
JP2018500380A (ja) 2014-12-31 2018-01-11 ノベルメド セラピューティクス,インコーポレーテッド アグリコシル化治療用抗体の製剤
JP7275027B2 (ja) * 2016-10-06 2023-05-17 アムジェン インコーポレイテッド 粘度低下タンパク質医薬製剤

Also Published As

Publication number Publication date
US20200155678A1 (en) 2020-05-21
MX2021005910A (es) 2021-08-16
BR112021009463A2 (pt) 2021-08-10
EP3883542A1 (en) 2021-09-29
WO2020106948A1 (en) 2020-05-28
US12036280B2 (en) 2024-07-16
SG11202104166QA (en) 2021-05-28
JP2022532965A (ja) 2022-07-21
KR20210093976A (ko) 2021-07-28
IL283229B2 (en) 2025-08-01
KR102944691B1 (ko) 2026-03-30
US20240316195A1 (en) 2024-09-26
IL283229B1 (en) 2025-04-01
CA3118306A1 (en) 2020-05-28
AU2019384160B2 (en) 2025-01-16
EA202191403A1 (ru) 2021-08-09
CN113164378A (zh) 2021-07-23
JP7637618B2 (ja) 2025-02-28
AU2019384160A1 (en) 2021-05-27
IL283229A (en) 2021-07-29

Similar Documents

Publication Publication Date Title
CL2018003582A1 (es) Composiciones para modular la expresión de c9orf72 (divisional solicitud 201702567)
MX2023011657A (es) Composiciones que comprenden curones y usos de los mismos.
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
MX2023010042A (es) Polinucleotidos moduladores.
SA519401246B1 (ar) (r) صياغات من-2- أمينو-3- فينيل بروبيل كربامات
MX2022001146A (es) Formulaciones de anticuerpos anti-pvrig y sus usos.
MY184813A (en) Oral care compositions and methods of use
EA201790273A1 (ru) Флагеллиновые композиции и их применение
PH12021550705A1 (en) Stable semaglutide compositions and uses thereof
MX2019007351A (es) Composiciones de aminoacidos y metodos de tratamiento de enfermedades hepaticas.
MX2025010681A (es) Formulaciones transdermicas
MY189820A (en) Oral care compositions and methods of using the compositions
EA201692422A1 (ru) Состав, содержащий пролекарство гемцитабина
MX2022014457A (es) Formulaciones de inmunoconjugado anti-cd79b estables.
MX2019004580A (es) Formulaciones farmaceuticas y metodos para prepararlas.
PH12020551618A1 (en) Erenumab compositions and uses thereof
WO2018183631A8 (en) Novel pharmaceutical formulations containing indirubin and derivatives thereof and methods of making and using the same
MX394051B (es) Composiciones que comprenden acido 15-hidroxieicosapentaenoico (15-hepe) y metodos de uso del mismo
MX391757B (es) Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico.
MX387731B (es) Composiciones farmacéuticas orales de mesalazina.
EA202090270A1 (ru) Новые замещенные производные ксантина
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
MX2020013389A (es) Composiciones de terlipresina y usos de las mismas.
TW201613977A (en) Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
JOP20200126B1 (ar) طرق استخدام وتركيبات تحتوي على دولاجلوتيد